Cipla, an Indian pharmaceutical company, has agreed to sell and distribute two of Eli Lilly’s best-selling diabetes treatments in India, the companies announced in a joint statement on Monday.
According to the companies, Lilly will transfer its rights in India to sell, promote, and distribute its Trulicity and Humalog products while maintaining its current operating model for the remainder of its product portfolio.
The deal will allow Cipla to expand access to the drugs in the country with the second-highest number of diabetic people in the world. India has more than 70 million adults with diabetes, according to government estimates.
Trulicity, a once-weekly shot to control blood sugar through the week, is Lilly’s best-selling drug that raked in sales of $1.54 billion in the second quarter. Its Humalog, a fast-acting insulin injection, is also a key part of its diabetes portfolio.
“Developing strategic partnerships to adopt different operating models is the key to… make innovative medicines available to more people in India,” said Luca Visini, Lilly’s managing director for the Indian subcontinent.
“Cipla has a strong local footprint and is well established to expand access to (Trulicity and Humalog) around India.”
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…